Please check your internet connection and try again.
# Durveqtix gene therapy
## Overview
Durveqtix (prademagenogene rozanolux) is a one-time gene therapy for adults and pediatric patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene that is amenable to exon skipping of dystrophin-240. It is designed to deliver a micro-dystrophin gene to muscle cells, aiming to produce a functional micro-dystrophin protein.
## Primary Indications
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older who have a confirmed mutation in the DMD gene amenable to exon skipping of dystrophin-240.
## Adult Dosing
The recommended dose is a single intravenous infusion of 3x10^13 vector genomes per kilogram (vg/kg).
## Pediatric Dosing
The recommended dose is a single intravenous infusion of 3x10^13 vector genomes per kilogram (vg/kg) for patients aged 4 years and older.
## Dose Adjustments
No dose adjustments are specified. The dose is weight-based.
## Contraindications
* None listed in the prescribing information. However, patients with pre-existing conditions that could be exacerbated by the administration or components of the therapy should be carefully evaluated.
## Adverse Effects
The most common adverse reactions reported include:
* Infusion-related reactions (e.g., fever, nausea, vomiting, headache, rash)
* Elevated liver enzymes (AST, ALT)
* Increased creatine kinase (CK)
* Troponin-I elevation
* Abdominal pain
* Headache
Serious adverse events may include liver injury, immune reactions, and complement activation.
## Key Drug Interactions
* **Immunosuppressants:** Concurrent use of immunosuppressants may increase the risk of certain adverse events.
* **Corticosteroids:** While often used in DMD management, the potential for additive effects on immune response or liver function with gene therapy should be considered.
* **Other Gene Therapies:** Concurrent administration with other gene therapies is not recommended.
## Monitoring
* **Liver Function:** Regular monitoring of liver enzymes (ALT, AST, bilirubin) is crucial before, during, and for at least 6 months after administration.
* **Muscle Enzymes:** Monitor creatine kinase (CK) levels.
* **Cardiac Function:** Monitor troponin-I and other cardiac markers as clinically indicated.
* **Immune Response:** Monitor for signs and symptoms of immune reactions.
* **Renal Function:** Assess renal function.
## Clinical Pearls
* Durveqtix is a one-time infusion.
* Pre-treatment with corticosteroids may be initiated prior to infusion to mitigate immune responses.
* Patients should be monitored closely for signs of liver injury, complement activation, and immune reactions.
* The long-term efficacy and safety of Durveqtix are still being established.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions. Dosing and safety information can change.*
